Company: AEMD
Filing Date: 2025-04-08
Form Type: PRE 14A
Source: 0001683168-25-002332
Chunk: 15

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-08
Form: PRE 14A
Chunk 15
---
RA healthcare premium costs for the same level of coverage Dr. Fisher
had during his employment with the Company, until the earliest of (i) twelve months from November 27, 2023, (ii) the date Dr. Fisher becomes
eligible for substantially equivalent healthcare coverage through another source, or (iii) the expiration of Dr. Fisher’s eligibility
for the continuation coverage. Further, and pursuant to the Separation Agreement, Dr. Fisher provided the Company with a general release
of all claims, effective November 27, 2023.

Employment Arrangements

We currently have written employment agreements with
our executive officers. For information about our employment agreements with our named executive officers, refer to “Executive and
Director Compensation — Employment Contracts.”

Equity Awards Granted to Executive Officers and Directors

We have granted stock options and RSUs to our executive
officers and directors. For information about our grants of stock option awards and RSUs to our named executive officers and our directors,
refer to “Executive and Director Compensation — Outstanding Equity Awards at 2024 Fiscal Year-End,” “Executive
and Director Compensation — Director Compensation for 2024 Fiscal Year” and “Executive and Director Compensation —
Non-Employee Director Compensation Policy.”

Indemnification Agreements

We have entered into and intend to continue to enter into indemnification agreements with each of our directors and our officers. The indemnification agreements, our Articles of Incorporation, as amended, and our Amended and Restated Bylaws require us to indemnify our directors and officers to the fullest extent permitted by Nevada law.

Policies and Procedures for Transactions with Related Persons

We maintain a written policy that our executive officers,
directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of
the immediate family or affiliate of any of the foregoing persons are not permitted to enter into a related person transaction with us
without the approval or ratification of the Audit Committee. Any request for us to enter into a transaction with an executive officer,
director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the
immediate family or affiliate of any of the foregoing persons, in which the amount involved exceeds $120,000 and such person would have
a direct or indirect interest, must be presented to the Audit Committee for review, consideration and approval. In approving or rejecting
any such proposal, the